Paul M. Burkat
Associate Professor of Clinical Psychiatry
Co-Medical Director Outpatient Psychiatry Center, University of Pennsylvania Perelman School of Medicine
Medical Director TEAM Clinic, University of Pennsylvania Perelman School of Medicine
Department: Psychiatry
Contact information
3535 Market Street
Philadelphia, PA 19104
Philadelphia, PA 19104
Education:
B.S. (Neuroscience)
University of Rochester, 1995.
Ph.D. (Pharmacology and Physiology)
University of Rochester School of Medicine and Dentistry, 2001.
M.D.
University of Rochester School of Medicine and Dentistry, 2003.
B.S. (Neuroscience)
University of Rochester, 1995.
Ph.D. (Pharmacology and Physiology)
University of Rochester School of Medicine and Dentistry, 2001.
M.D.
University of Rochester School of Medicine and Dentistry, 2003.
Post-Graduate Training
Intern, University of Wisconsin Hospitals and Clinics, 2003-2004.
Postdoctoral Researcher, Department of Anesthesiology, University of Wisconsin Hospitals and Clinics, 2004-2006.
Resident in Anesthesiology, Milton S. Hershey Medical Center, 2004-2004.
Resident in Psychiatry, University of Rochester Medical Center, 2006-2010.
Permanent linkIntern, University of Wisconsin Hospitals and Clinics, 2003-2004.
Postdoctoral Researcher, Department of Anesthesiology, University of Wisconsin Hospitals and Clinics, 2004-2006.
Resident in Anesthesiology, Milton S. Hershey Medical Center, 2004-2004.
Resident in Psychiatry, University of Rochester Medical Center, 2006-2010.
Selected Publications
Burkat, PM: Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling of Alprazolam: Implications for Anxiety and Addiction. Br J Clin Pharmacol 89(8): 2569-2581, August 2023.Burkat, PM. : Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling of Diazepam: Unbound Interstitial Brain Concentrations Correspond to Clinical End Points. J Clin Pharmacol. 62(10): 1297-1309, Oct 2022.
Burkat PM, Lor C, Perouansky M, Pearce RA. : Enhancement of α5-containing γ-aminobutyric acid type A receptors by the nonimmobilizer 1,2-dichlorohexafluorocyclobutane (F6) is abolished by the β3(N265M) mutation. Anesth Analg 119(6): 1277-1284, Dec 2014.
Gingrich KJ, Burkat PM, Roberts WA. : Pentobarbital produces activation and block of alpha1beta2gamma2S GABA(A) receptors in rapidly perfused whole cells and membrane patches: divergent results can be explained by pharmacokinetics. J Gen Physiol 133(2): 171-188, Feb 2009.
Burkat PM, Yang J, Gingrich KJ. : Dominant gating governing transient GABA(A) receptor activity: a first latency and Po/o analysis. J Neurosci. 21(18): 7026-7036, Sep 2001.
Gingrich KJ, Burkat PM.: Zn2+ inhibition of recombinant GABAA receptors: an allosteric, state-dependent mechanism determined by the gamma-subunit. J Physiol 506: 609-25, Feb 1998.